Complete Depletion of Daratumumab Interference in Serum Samples from Plasma Cell Myeloma Patients Improves the Detection of Endogenous M-Proteins in a Preliminary Study

Background: Therapeutic humanized IgG1 kappa monoclonal antibody (t-mAb), daratumumab (DARA) is a Food and Drug Administration approved drug for the treatment of relapsed/refractory plasma cell myeloma (PCM). DARA appears on serum protein electrophoresis (SPEP) and on serum immunofixation (sIFE) as...

Descripción completa

Detalles Bibliográficos
Autores principales: Vakili, Hana, Koorse Germans, Sharon, Dong, Xiuhua, Kansagra, Ankit, Patel, Hetalkumari, Muthukumar, Alagarraju, Hashim, Ibrahim A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7235820/
https://www.ncbi.nlm.nih.gov/pubmed/32295157
http://dx.doi.org/10.3390/diagnostics10040219

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7235820/
https://www.ncbi.nlm.nih.gov/pubmed/32295157
http://dx.doi.org/10.3390/diagnostics10040219

Ejemplares similares